Welcome to the DDReg Knowledge Capsule!In this episode, we unpack the rapidly changing global regulatory landscape for biosimilar development across key target markets: the US (FDA), European Union (EMA), UK (MHRA), China (NMPA/CDE), and Japan (PMDA).We examine the pivotal 2026 transition away from routine comparative clinical efficacy trials toward tailored, risk-based evaluation frameworks grounded in high-resolution comparative analytical data, pharmacokinetic (PK) studies, and immunogenicity assessments.Key topics covered in this episode:

• • Tailored Evidence Pathways: How regulators like the FDA, EMA, MHRA, and PMDA are evaluating biosimilarity without automatically requiring comparative efficacy studies.
  • Reference Product Selection & Bridging: Navigating jurisdiction-specific reference rules and establishing scientific bridging between foreign comparators and local originators.
  • Global Core Strategy: Designing one unified scientific dossier with planned regional adaptations to avoid duplicated clinical trials and submission delays

Visit our blog - https://resource.ddregpharma.com/blogs/global-biosimilar-regulatory-strategy/

Welcome to DDReg Knowledge Capsule! In this episode, we explore Health Canada's regulatory framework for registering biosimilar biologic drugs. We break down the fundamental differences between biosimilars and generic small-molecule drugs, explain why biosimilars are authorized through the New Drug Submission (NDS) pathway, and discuss the pivotal role of the Canadian Reference Biologic Drug (CRBD). Listeners will also gain actionable insights into scientific reviews by the Biologic and Radiopharmaceutical Drugs Directorate (BRDD), indication extrapolation requirements, and post-market pharmacovigilance obligations
Check out our blog - https://resource.ddregpharma.com/blogs/biosimilar-registration-in-canada-guide/

This episode explores how pharmaceutical organisations can effectively structure regulatory roles across global, regional, and local markets. Based on the DDReg guide to global regulatory operating models, the discussion highlights the strategy of "controlled decentralization"—maintaining global consistency for core scientific positions while ensuring local authority ownership where jurisdiction-specific knowledge is critical.Key topics covered include:

• The five-layer operational structure: Defining decision rights across enterprise regulatory governance, product strategy, regional translation, local execution, and regulatory operations.
• Cross-functional coordination: Clarifying accountabilities between regulatory affairs, clinical development, CMC/quality, pharmacovigilance, and supply chain functions.
• Modern data standards & technology: How eCTD v4.0, ISO IDMP master data standards, Regulatory Information Management (RIM) systems, and AI in 2026 are reshaping regulatory workflows and data governance

Welcome to DDReg Knowledge Capsule! In this episode, we dive into the complex world of global post-approval change management in the pharmaceutical industry.When a drug product undergoes a single internal scientific or manufacturing modification—such as a site transfer, process modification, or analytical method update—it can trigger dozens of distinct regulatory submissions across international jurisdictions. This episode explores why global pharmaceutical companies must separate the globally controlled scientific change from market-specific regulatory pathways.For more, visit our blog: https://resource.ddregpharma.com/blogs/global-variation-management-post-approval-change/

Welcome to the DDREG Knowledge Capsule. In this episode, we unpack the National Pharmaceutical Regulatory Agency's (NPRA) landmark 2026 reliance pilot pathway in Malaysia. We explore how eligible biosimilars with prior US FDA or EMA approval can now access an accelerated 60-working-day registration timeline.However, this rapid timeline is far from automatic. We break down the strict parameters sponsors must navigate to succeed, including the critical three-month post-approval submission window, rigorous dossier sameness requirements, and NPRA-specific local additions like ASEAN Zone IVb stability data. Tune in to discover how global biopharma teams can proactively adapt their launch strategies to successfully leverage this new pathway
For more ready this blog - https://resource.ddregpharma.com/blogs/biosimilar-registration-malaysia-npra/

Welcome to this episode of the DDReg Knowledge Capsule. In this session, we break down Germany's critical regulatory transition from the national DMIDS database to the EU-wide EUDAMED platform. We explore the operational modules that became mandatory on 28 May 2026—including Actor Registration, UDI/Device Registration, Notified Bodies & Certificates, and Market Surveillance—and clarify the upcoming 28 November 2026 transition deadline for legacy and MDR/IVDR devices. Listeners will learn about the process for validating Single Registration Numbers (SRNs) in Germany, the special requirements for non-EU manufacturers working with authorised representatives, and how to avoid costly compliance errors like assuming automatic data migration from DMIDS.
For more, visit our blogs: https://resource.ddregpharma.com/blogs/eudamed-mandatory-registration-germany-bfarm/

India is evolving from "the pharmacy of the world" to a powerhouse of pharmaceutical innovation, focusing on biosimilars, complex generics, and advanced therapies. In this episode, we unpack how this transition is fundamentally reshaping global regulatory strategies, clinical trial expectations, and FDA compliance for companies targeting international marketsVisit our blog for more: https://resource.ddregpharma.com/blogs/india-pharmaceutical-industry-innovation/

Why do even the most revolutionary gene therapies with promising clinical results face critical roadblocks on their path to commercial approval? In this episode of the DDReg Knowledge Capsule, we delve deep into the core reasons behind Biologics License Application (BLA) delays, focusing on common Chemistry, Manufacturing, and Controls (CMC) pitfalls, weak analytical strategies, and limited comparability data.We unpack the regulatory expectations of the FDA’s Center for Biologics Evaluation and Research (CBER) and the Office of Therapeutic Products (OTP), highlighting why early regulatory alignment, rigorous product characterisation, and proven manufacturing consistency are absolutely vital for success. Whether you are navigating vector-related complexities, scale-up challenges, or preparing for critical pre-BLA meetings, this episode provides the strategic insights needed to ensure your manufacturing, clinical, and quality teams are fully aligned for FDA readinessRead this Blog: https://resource.ddregpharma.com/blogs/gene-therapy-bla-submission-regulatory-strategy/

Welcome to the DDReg Knowledge Capsule. In this episode, we unpack the historic shift in the UAE’s healthcare regulatory framework as the Emirates Drug Establishment (EDE) takes over medical device oversight from the Ministry of Health and Prevention (MOHAP). Established under Federal Decree-Law No. 38 of 2024, the EDE centralizes compliance across all seven emirates. We discuss critical updates for manufacturers and distributors, from key technical dossier requirements (such as CE Marks and FDA clearances) to the new 45-working-day completion timeline and the 5-year marketing authorization validity. Tune in to discover how to align your regulatory strategy and secure faster access to the UAE market.https://resource.ddregpharma.com/blogs/uae-mohap-to-ede-transition-medical-devices-regulations/

Welcome to the DDReg Knowledge Capsule! In this episode, we explore the major regulatory milestone of 1 January 2026, when the Jordan Food and Drug Administration (JFDA) became the 57th Participating Authority of the Pharmaceutical Inspection Co-operation Scheme (PIC/S).As only the second Arab nation to achieve full PIC/S membership, Jordan is significantly boosting its standing as a reliable pharmaceutical manufacturing hub in the MENA region. We break down what this strategic shift means for manufacturers in practice—from the transition to more rigorous, risk-based inspections to elevated global GMP compliance expectations spanning quality systems, data integrity, and validation. Listen in to find out how businesses can proactively adapt to Jordan's new regulatory landscape and leverage it to secure stronger international partnerships and enhanced market access
https://resource.ddregpharma.com/blogs/jordan-pics-membership-gmp-compliance/